Pharma Biz: ZIM Labs plans Rs. 220 crore investment to foray into Europe, US markets

The Nagpur-based ZIM Laboratories, a leading provider of new drug delivery systems, has embarked on an initiative to expand its presence in Europe and US markets over the next three years with an investment of Rs. 220 crore and broaden portfolio of novel and differentiated drug delivery solutions.

Currently the firm is in talks with co-partners and distribution channels in Europe to start business activities by 2019 and will soon commence product registration there. Next step will be US market. For this, we are planning to set up a plant spanning over 6 acres of land in Multi-Modal International Air Cargo and Hub (MIHAN), Nagpur which we procured recently. The plant will develop products for US market after it is approved by US FDA. The products ranges from complex generics to drugs that went off patent over the last couple of years and drugs that will go off patent from 2018-2022, said Anwar S Daud, managing director of ZIM Labs.

Original Article

Popular posts from this blog

ZIM Labs’ Dr. Nidhi Sapkal addressed 2nd Annual Innogen India Summit 2017

ZIM Serves Local Education Institute in Sanitation

ZIM Laboratories participates at CPhI Korea